Avanza Fonder AB Purchases 1,590 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Avanza Fonder AB raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,187 shares of the biopharmaceutical company’s stock after buying an additional 1,590 shares during the period. Avanza Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $9,407,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in REGN. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $31,000. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. Caitlin John LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, Berbice Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on REGN shares. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Royal Bank Of Canada upped their target price on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $736.53 on Tuesday. The company has a 50 day simple moving average of $764.72 and a two-hundred day simple moving average of $702.84. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a market capitalization of $77.87 billion, a price-to-earnings ratio of 17.72, a P/E/G ratio of 1.97 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $12.07 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.